Teligent Inc. recently announced that the U.S. Food and Drug Administration (FDA) has granted approvals for its abbreviated new drug applications (ANDAs) for Triamcinolone Acetonide Lotion USP, 0.1 percent and Triamcinolone Acetonide Lotion USP, 0.025 percent.
With these two approvals, Teligent, a specialty generic pharmaceutical company based in New Jersey, has now had seven ANDAs for a pipeline of topical generic pharmaceutical products that are developed internally approved by the FDA.
"We are excited to add these two new products to our growing portfolio of topical prescription medicines," President and CEO of Teligent Jason Gernfell-Gardner said. "We have now received six approvals from the FDA this year, including an earlier approval of a partnered submission. Our team is committed to bringing these products to market this quarter.''
Data release by IMS Health in May of this year show that the potential market for these two new products is an estimated $6.8 million.